NCT01665417 2017-02-08
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
Betta Pharmaceuticals Co., Ltd.
Nottingham University Hospitals NHS Trust
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.